Stephen Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, posted on X:
“PET surveillance in NSCLC after definitive therapy.
SUPE_R trial randomized 750 patients to PET/CT or CT alone.
PET increased detection of recurrence, but no difference in those treated with curative intent (48%); no difference in survival (HR 0.97).”
“Surveillance with [18F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial.”
Authors: Kasper Foged Guldbrandsen et al.
